EFEMP1 as a Potential Biomarker for Diagnosis and Prognosis of Osteosarcoma.
Adolescent
Adult
Animals
Biomarkers, Tumor
/ blood
Bone and Bones
/ metabolism
Cell Line, Tumor
Disease Models, Animal
Extracellular Matrix Proteins
/ blood
Female
Humans
Lung
Lung Neoplasms
/ diagnosis
Male
Mice
Mice, Inbred BALB C
Mice, Nude
Neoplasm Metastasis
Osteosarcoma
/ diagnosis
Patients
Prognosis
Young Adult
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
07
2019
revised:
23
12
2019
accepted:
12
02
2020
entrez:
14
4
2020
pubmed:
14
4
2020
medline:
8
1
2021
Statut:
epublish
Résumé
Osteosarcoma (OS) is the most common primary bone malignancy. Our previous study revealed an association between the level of epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) and the invasion, metastasis, and poor prognosis of OS. However, the exact correlation between the serum EFEMP1 level and OS diagnosis and progression was unclear. This study is aimed at determining the value of the serum EFEMP1 level in the diagnosis and prognosis of OS. Fifty-one consecutive OS patients were prospectively registered in this study. The serum EFEMP1 levels were measured using ELISA at diagnosis, after neoadjuvant chemotherapy, and before and after surgical treatment. Sixty-nine healthy subjects in the control group, nine patients with chondrosarcoma, and 12 patients with giant cell tumor of the bone were also enrolled in this study. Surgical orthotopic implantation was used to generate a mouse OS model, and the correlation between the circulating EFEMP1 levels and tumor progression was examined. Then, OS patients had significantly higher mean serum EFEMP1 levels (7.61 ng/ml) than the control subjects (1.47 ng/ml). The serum EFEMP1 levels were correlated with the Enneking staging system (
Identifiants
pubmed: 32280689
doi: 10.1155/2020/5264265
pmc: PMC7115049
doi:
Substances chimiques
Biomarkers, Tumor
0
EFEMP1 protein, human
0
Efemp1 protein, mouse
0
Extracellular Matrix Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5264265Informations de copyright
Copyright © 2020 Zhuo Wang et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Oncol Rep. 2016 Jun;35(6):3489-95
pubmed: 27108677
Arthritis Rheum. 2012 Jul;64(7):2260-7
pubmed: 22275171
Exp Eye Res. 2010 Mar;90(3):374-5
pubmed: 19799900
J Bone Oncol. 2015 Oct 30;4(3):80-4
pubmed: 26587373
Biomed Pharmacother. 2017 May;89:957-965
pubmed: 28292024
Mol Cancer Res. 2009 Feb;7(2):189-98
pubmed: 19208748
PLoS One. 2013 Nov 13;8(11):e78783
pubmed: 24236050
Transl Lung Cancer Res. 2017 Jun;6(3):259-269
pubmed: 28713671
BMC Cancer. 2017 Jun 15;17(1):419
pubmed: 28619014
Oncogene. 2017 Sep 14;36(37):5243-5251
pubmed: 28504717
Acta Ortop Bras. 2016 May-Jun;24(3):142-6
pubmed: 27217815
N Engl J Med. 2012 Oct 11;367(15):1417-27
pubmed: 23050525
Int J Cancer. 2015 Oct 15;137(8):1830-41
pubmed: 25857718
Oncotarget. 2015 Jun 10;6(16):14191-208
pubmed: 25987128
Eur Rev Med Pharmacol Sci. 2015 Nov;19(21):4076-80
pubmed: 26592829
Med Sci Monit. 2017 Jan 13;23:216-222
pubmed: 28085790
Arthritis Rheumatol. 2017 Mar;69(3):576-585
pubmed: 27780308
Oncogene. 2015 Nov 5;34(45):5635-47
pubmed: 25823021
Cancer Biomark. 2018 Feb 6;21(2):449-454
pubmed: 29125481
Clin Lab. 2017 Oct 1;63(10):1717-1722
pubmed: 29035461